Schmitt, Frederick A., Aarsland, Dag, Brønnick, Kolbjørn S., Meng, Xiangyi, Tekin, Sibel, Olin, Jason T.

Rivastigmine has been shown to improve cognition in patients with Parkinson’s disease dementia (PDD). To further explore the impact of anticholinesterase therapy on PDD, Alzheimer’s Disease Assessment Scale—cognitive subscale (ADAS-cog) items were assessed in a retrospective analysis of a 24-week, double-blind, placebo-controlled trial of rivastigmine. Mean changes from baseline at week 24 were calculated for […]

Cummings, Jeffrey, Froelich, Lutz, Black, Sandra E., Bakchine, Serge, Bellelli, Giuseppe, Molinuevo, José L., Kressig, Reto W., Downs, Pamela, Caputo, Angelika, Strohmaier, Christine

Aim: Determine whether patients with Alzheimer’s disease demonstrating functional and cognitive decline, following 24-48 weeks of open-label treatment with 9.5 mg/24 h (10 cm(2)) rivastigmine patch, benefit from a dose increase in a double-blind (DB) comparative trial of two patch doses.; Methods: Patients meeting prespecified decline criteria were randomized to receive 9.5 or 13.3 mg/24 […]

Kulkantrakorn, Kongkiat, Tanyakitpisal, Panas, Towanabut, Somchai, Dejthevaporn, Charungthai, Rangseekajee, Poonsri, Pongpakdee, Sunsanee, Laptikultham, Somsak, Rodprasert, Kritsada, Setthawatcharawanich, Suwanna, Thinkhamrop, Bandit

Background: Rivastigmine is a cholinesterase inhibitor for treatment of mild to moderate Alzheimer’s disease (AD) and dementia associated with Parkinson’s disease. The new patch formulation was recently made available. We assessed the safety, tolerability, and cognitive outcome of rivastigmine patch in treatment of mild to moderate AD in clinical practice in Thailand.; Methods: A multicentre, […]

Grossberg, G., Cummings, J., Frolich, L., Bellelli, G., Molinuevo, J. L., Krahnke, T., Strohmaier, C.

Background: Stabilizing/reducing decline in the ability to perform activities of daily living (ADLs) is important in management of Alzheimer’s disease (AD).; Methods: Post hoc analysis of OPtimizing Transdermal Exelon In Mild-to-moderate Alzheimer’s disease (OPTIMA), a double-blind trial comparing 13.3 and 9.5 mg/24 h rivastigmine patch in patients with AD demonstrating functional and cognitive decline with […]